1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus

BACKGROUND: Glycopeptides and lipopeptides, more specifically vancomycin (VAN) and daptomycin (DAP) have been principally utilized in treating MRSA infections. Due to continued use, MRSA strains have developed resistance to these antibiotics including vancomycin intermediate susceptible Staphylococc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Abdul-Mutakabbir, Jacinda, Kebriaei, Razieh, Stamper, Kyle, Maassen, Philip, Rybak, Michael J
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808787/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1403
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares